Sonus discusses new agent at AHA show
Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation
Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation agent that studiesindicate may be capable of producing myocardial perfusion at lowdoses with no hemodynamic effects.
Researchers from the University of California at San Diegoworking with the new agent presented data from animal studiesfor the first time at a major medical conference. QW7437 is aphase-shift emulsion that is stabilized with a negative-chargedsurfactant.
Investigators at the AHA meeting also presented data on thecompany's lead EchoGen agent, including an animal study by DukeUniversity researchers in which EchoGen was used to make 3-D measurementsof the left ventricle muscle mass in a single cardiac cycle.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
